More from these Authors

• Case | HBS Case Collection | January 2020

  Salary Finance US

  John R. Wells and Benjamin Weinstock

  In October 2019, Dan Macklin, the newly-appointed chief executive of Salary Finance Inc., was weighing his options for the future of the business. The company’s value proposition was quite simple: partner with employers to offer employees affordable loans that were repaid through automatic payroll deductions. Taking repayments directly from salary, and collecting those repayments in one transaction from the employer, dramatically reduced costs, saving employees large amounts of interest when compared to market alternatives like credit cards or payday lenders.
  Salary Finance Inc. was a subsidiary of Salary Finance Limited which was launched in the UK in 2015. By September 2018, Salary Finance Limited had partnered with over 100 UK employers and offered loans to around one million employees. It was at this point that the company decided to try and replicate this success in the United States, and opened an office in Boston, Massachusetts. By October 2019, the US business had partnered with 15 employers, offering loans to around 50,000 employees.
  In October 2019, Macklin was contemplating the best way to accelerate the growth of Salary Finance Inc. to hit his 10 million employee target. He was also wrestling with whether he should stick with the core product or add new products to drive sales. This had worked well in the UK where pay advances and savings accounts had proven popular in addition to their core loan product. Salary Finance Inc. was off to a good start, but it remained uncertain how quickly Macklin could grow the business and help more Americans get out of debt.

  Keywords: Employees; Credit; Financing and Loans; Wages; Innovation and Invention; Expansion; Growth Management; Decision Making; Financial Services Industry; United States;

  Citation:

  Wells, John R., and Benjamin Weinstock. "Salary Finance US." Harvard Business School Case 720-421, January 2020.  View Details

  CiteView DetailsEducators

  Related

• Case | HBS Case Collection | January 2020

  Celata Bioinnovations

  John R. Wells and Benjamin Weinstock

  In December 2019, Jon Hu (Harvard Business School MBA, 2019) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process. Celata’s platform used novel data types and a unique data integration process to generate hypotheses about proteins that were involved in the formation and progression of disease. They believed the platform was better and faster at identifying actionable biological targets, increasing the speed of discovery and reducing the chances of failure, promising to lower costs and bring drugs to market more quickly. Their platform had achieved proof of concept during Strasser’s PhD research at Massachusetts Institute of Technology (MIT), when it helped identify and validate a target related to Inflammatory Bowel Disease (IBD) in mouse models. However, full validation wouldn’t come until their platform was used to develop a drug that successfully treated a disease in humans, a process that could take several years.
  In the first instance, Celata’s platform was best suited to identify targets for cancers, inflammatory diseases, and neurodegenerative diseases, which collectively presented a global market opportunity of over $200 billion. However, Hu and Strasser were debating which opportunities to pursue. Should they try to improve the efficacy of current drugs, or go for brand new opportunities, indications for which there were no solutions on the market? And if they focused on the latter, should they just look for large market opportunities, or include “orphan” diseases, for which there was a relatively small market? Should they look for small molecule drug candidates, or include large molecule biologics in their search? And where should they operate in the drug development pipeline? At one extreme, they could sell potential drug candidates to established pharmaceutical companies; at the other, they could “go full pharma” and build a new pharmaceutical company themselves.

  Keywords: drug development; drug discovery; Drug Trials; Pharmaceutical Companies; Pharmaceutical Company; Pharmaceuticals; therapeutics; Biologics; biotech; biotechnology; biopharmacy company; biochemistry; technology commercialization; technology companies; Drug Testing; Startup; start-up; Startups; start-ups; Startup financing; strategic decision making; strategic decisions; strategic evolution; FDA; Food and Drug Administration; clinical trials; disease management; market attractiveness; Market entry; market opportunities; Health Disorders; Technological Innovation; Technology; Commercialization; Business Startups; Finance; Decision Making; Strategy; Market Entry and Exit; Opportunities; Pharmaceutical Industry; Biotechnology Industry;

  Citation:

  Wells, John R., and Benjamin Weinstock. "Celata Bioinnovations." Harvard Business School Case 720-427, January 2020.  View Details

  CiteView DetailsEducatorsPurchase

  Related

• Case | HBS Case Collection | January 2020

  Wuxi Lead Intelligent Equipment Co., Ltd.

  John R. Wells and Benjamin Weinstock

  In 2019, Wuxi Lead Intelligent Equipment Co., Ltd. (Lead) was the largest supplier of lithium-ion rechargeable battery manufacturing equipment in the world. Based in Wuxi, China, the company generated RMB 3.9 billion ($557 million) in revenues in 2018, up from RMB 175 million five years earlier, for a compound annual growth of 86%. Almost 90% of sales came from the lithium-ion battery market, and Lead supplied most of the major manufacturers in China, Korea, and Japan, and Tesla in the United States. The company was floated on the Shenzhen Stock Exchange in 2015, and, in early December 2019, was valued at over RMB 33 billion. Lead’s meteoric rise had made its charismatic founder Wang Yanqing the 205th richest man in China.
  However, all was not well in the rechargeable battery market in 2019. The Chinese battery and electric vehicle markets had received significant subsidies over the years, but these were slowly being withdrawn. In early 2019, the Chinese Government announced that subsidies on electric cars would drop by 50% at the end of June 2019. On the announcement, stock prices across the sector fell sharply. Electric car sales in July and August 2019 were down, but most observers believed that the set-back was short-term and that growth would continue to be strong in the long term. However, many expected rapid consolidation in the battery manufacturing and electric vehicle markets, as marginal players were forced out by mounting competitive pressure.
  Lead’s revenues for the twelve months ending September 30, 2019 were up 13% on 2018 revenues, well behind the 79% growth enjoyed in 2018 compared to 2017. However, the company’s stock price in early December 2019 remained strong at RMB 38 per share, 40% ahead of a year earlier.
  Yanqing, who remained majority shareholder in the company in 2019, was optimistic: “We are facing a short-term setback as subsidies are reduced, but the battery and EV markets will soon recover. And we have many other options at Lead. The challenge is which to focus on.”

  Keywords: lithium-ion batteries; electric vehicles; government subsidies; industry dynamics; Markets; Change; Strategy; Decision Making; Manufacturing Industry; China;

  Citation:

  Wells, John R., and Benjamin Weinstock. "Wuxi Lead Intelligent Equipment Co., Ltd." Harvard Business School Case 720-419, January 2020.  View Details

  CiteView DetailsEducators

  Related